Patients with neurological disorders often require chronic support with enteral nutrition (EN) because of problems with eating and swallowing (Munakata 2008) . For these patients, the intake of essential fatty acids depends primarily on the EN. There are two essential fatty acids for humans: linoleic acid (LA) and α -linolenic acid (ALA) (Gerster 1995) and deficiency in these essential fatty acids can cause clinical symptoms (Richardson and Sgoutas 1975; Holman et al. 1982; Bjerve et al. 1987) .
Linoleic acid is the parent of the n-6 fatty acids, which are defined by the position of the first double bond between the 6th and 7th carbons counted from the terminal methyl group of the molecule. LA is transformed into long-chain n-6 polyunsaturated fatty acids (PUFAs), including arachidonic acid (AA). ALA is a precursor of n-3 fatty acids, which have the first double bond between the 3rd and 4th carbons. ALA is further transformed into long-chain n-3 PUFAs such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA); in vivo, however, the formation of EPA and DHA from ALA is limited in humans (Brenna 2002; Burdge et al. 2002) . Given that the n-6 and n-3 series are not interchangeable thorough biotransformation, the systemic fatty acid status of patients receiving EN is influenced by the fatty acid composition of the EN formula (Kumode 2003) .
Long-chain PUFAs such as AA, EPA, and DHA pos-sess intrinsic physiological significance. AA is metabolized into multiple bioactive eicosanoids via the AA cascade. EPA, DHA, and their metabolites competitively inhibit the overproduction of AA-related eicosanoids, thereby suppressing aberrant inflammatory reactions, blood coagulation, and the risk of ischemic heart disease (Kinsella et al. 1990; Gerster 1995; Aiko et al. 2005) . In addition, highlevel accumulation of DHA in the brain plays a role in the development of learning and cognitive functions (Innis 2007) . Therefore, it is important to monitor and optimize the systemic fatty acid balance in patients receiving longterm EN. The EN formulas that are used clinically in Japan contain various amounts of LA and ALA and are characterized by a wide range of n-6 to n-3 fatty acid ratios. Most available EN formulas do not contain AA, EPA, or DHA, although some formulas include EPA and DHA. The large variation in fatty acid content among EN formulas would be expected to result in differences in the fatty acid status of patients receiving prolonged EN. This study assessed the effects of EN formulas with different fatty acid compositions on the fatty acid status of these patients.
PATIENTS AND METHODS
We examined sera from 50 patients (29 males and 21 females) with neurological diseases who had been receiving EN continuously for longer than 1 year (> 1 year, n = 5; > 3 years, n = 4; > 5 years, n = 41) in hospitals in Miyagi, Japan. The neurological diseases in these patients were cerebral palsy (spastic, n = 30; dyskinetic, n = 1), sequelae of encephalopathy or encephalitis (n = 13), juvenile Parkinson's disease (n = 1), progressive dystonia (n = 1), chromosome 4p-syndrome (n = 1), Tay-Sachs disease (n = 1), xeroderma pigmentosum (n = 1), and dentatorubral-pallidoluysian atrophy (n = 1). All patients were non-ambulatory and received almost their entire nutritional intake from artificial liquid feeding via a nasogastric tube or gastrostomy.
The patients were retrospectively divided into the following four groups based on the fatty acid composition of the EN formula that was used for each patient. The profiles of the patients in each group along with the fatty acid compositions of the respective EN formulas used are summarized in Table 1 . All the EN formulas were commercially available and the compositions of the EN formulas were obtained from the manufacturers' data. For all of the EN formulas used, 1.0 ml of EN solution contained approximately 1.0 kcal. In the high, intermediate, and low n-6 to n-3 ratio (n-6/n-3) EN groups, patients receiving EN formulas with similar compositions were placed in one group. Therefore, two values are given for the EN formulas in these groups. In the EPA + DHA-containing EN group, patients received a single type of EN formula.
High n-6/n-3 EN group: In the EN formulas used in this group, the LA concentration was high and the ALA concentration was very TABLE 1. Summary of the patient groups and the compositions of the enteral nutrition (EN) formula used in each group.
High n-6/n-3
Intermediate n-6/n-3 Low n-6/n-3 EPA + DHA-containing
Receiving formula with high n-6/n-3 ratio
Receiving formula with moderate n-6/n-3 ratio
Receiving formula with low n-6/n-3 ratio
Receiving formula containing EPA and DHA with low n-6/n-3 ratio The patients receiving long-term EN were retrospectively divided into four groups based on the fatty acid composition of the EN formula used. *n, number of patients receiving each kind of EN formula. In the high, intermediate, and low n-6 to n-3 ratio (n-6/n-3) EN groups, patients receiving EN formulas with similar compositions were placed in one group. Therefore, two values are given for the EN formulas in these groups. In the EPA + DHA-containing EN group, patients received a single type of EN formula. The fatty acid compositions of the formulas were obtained from the manufacturers' data. Data are expressed as means ± S.D. LA, linoleic acid; ALA, α -linolenic acid; AA, arachidonic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid. low, resulting in extremely high n-6 to n-3 fatty acid concentration ratios (n-6/n-3 ratios) of 34 or 44. The formulas did not contain EPA or DHA.
Intermediate n-6/n-3 EN group: The EN formulas used in this group were characterized by an increased ALA concentration. The LA concentration remained high, resulting in moderately high n-6/n-3 ratios of 8.79 or 8.96. The formulas did not contain EPA or DHA.
Low n-6/n-3 EN group: For the EN formulas in this group, the ALA concentration was almost identical to that in the intermediate n-6/n-3 group, but the LA concentration was markedly reduced, giving lower n-6/n-3 ratios of 3.0 or 3.94, which is lower than the ratio (4.0) recommended as the dietary allowance for Japanese individuals (Sugano 1996) . The formulas did not contain EPA or DHA.
EPA + DHA-containing EN group: Patients in this group received an EN formula containing EPA and DHA. Both LA and ALA were also included, at an n-6/n-3 ratio of 3.6.
The patients received EN three or four times a day. Blood samples were obtained just before injecting the EN solutions, after a 6-to 8-h fast. Then, the serum was separated and stored at −20°C until analysis. In a separate procedure, fasting blood samples were obtained from normal healthy volunteers who habitually consumed balanced diets (n = 20; mean age, 31 ± 13 years; 9 males, 11 females). The objectives of this study were explained to the patients' families and to the volunteers, and informed consent was obtained from the parents or guardians of all patients and from the volunteers. The study protocol was approved by the ethics committee of Takuto Rehabilitation Center for Children, Sendai, Japan.
Total lipids were extracted from serum (0.3-0.5 ml) using a chloroform-methanol mixture (2 : 1 by vol), methyl behenate (Funakoshi, Tokyo, Japan) as an internal standard and butylated hydroxytoluene (Wako Pure Chemical Industries, Osaka, Japan) as an antioxidant (Folch et al. 1957; Chida et al. 1972 ). The total lipid extract was stored in dry chloroform before transmethylation. An aliquot of each lipid extract was dried under N 2 and saponified at 95°C for 60 min in KOH-methanol. The fatty acids in the saponified fraction were methylated with 14% BF 3 in methanol at 95°C for 2 min. The methyl esters were disorbed in hexane and injected into a gas chromatograph equipped with a flame-ionization detector (model 6890N; Agilent technologies, Santa Clara, CA, USA). Separations were performed on a capillary column (0.25 mm × 30 m, DB-WAX; Agilent technologies, Santa Clara, CA, USA). The column temperature was initially 150°C and was increased at a rate of 2°C/min to a final column temperature of 220°C, which was maintained for 15 min. The injector and detector temperatures were 250°C. Helium was used as the carrier gas, with a splitter ratio of 1 : 50 and a linear gas velocity of 30 cm/s.
All statistical analyses were performed using R (R Development Core Team 2005; http://www.r-project.org). Regression lines (Figs. 1 and 2) were determined using a least squares fitting routine after logarithmic transformation of the n-6/n-3 ratios. Pearson's correlation coefficient was calculated and tested for significance. Data for the group analyses are presented as means ± standard deviation (Table 2) . Statistical significance of differences between two groups was tested using the Mann-Whitney test. The Kruskal-Wallis test was used to test across high, intermediate, and low n-6/n-3 EN groups.
RESULTS
The measured values for the n-3 fatty acids (ALA, EPA, and DHA) and n-6 fatty acids (LA and AA) are plotted Data from the other three groups are plotted against the logarithmic axis of the n-6/n-3 ratio of the EN formula used for each patient; Low, low n-6/n-3 EN group; Intermed, intermediate n-6/n-3 EN group; High, high n-6/n-3 EN group. The solid line indicates the fit to a logarithmic function using the least squares method. r, correlation coefficient.
in Figs. 1 and 2 , respectively. In the high, intermediate, and low n-6/n-3 EN groups, in which the formulas contained no EPA or DHA, the serum concentrations of ALA, EPA, and DHA increased significantly as the n-6/n-3 ratio was reduced. Conversely, the LA level decreased significantly as the n-6/n-3 ratio was reduced. The AA concentration tended to be low at a low n-6/n-3 ratio, although this trend was not significant. In formulas containing preformed EPA and DHA, the serum EPA and DHA levels had distributions similar to those of the control values, whereas the LA and AA levels tended to be lower than the control values in the statistical analysis (Table 2) . Table 2 summarizes the values for the fatty acids and the results of the statistical analyses among the groups. In the sera from the high and intermediate n-6/n-3 EN groups, the serum levels of ALA, EPA, and DHA were significantly lower than those in the control group, whereas the LA and AA levels were not significantly different from those in the control group. The ALA and EPA levels in the intermediate n-6/n-3 EN group tended to be higher than those in the high n-6/n-3 EN group, although there were no significant differences in any of the serum fatty acids tested between these b Significant differences between low n-6/n-3 and EPA+DHA-containing EN groups (Mann-Whitney test; p < 0.05). No significant differences were detected in any fatty acid between the high and intermediate n-6/n-3 EN groups.
c p-values among the low, intermediate, and high n-6/n-3 EN groups were determined using the Kruskal-Wallis test.
groups. The low n-6/n-3 EN group exhibited significantly higher serum EPA and DHA levels than those in the intermediate n-6/n-3 EN group, but the EPA and DHA levels were still significantly lower than those in the control group. Conversely, the serum concentrations of ALA, EPA, and DHA reached control values in the EPA+DHA-containing EN group. The LA and AA levels were significantly lower in the sera from the low n-6/n-3 EN and EPA + DHAcontaining EN groups, but the other groups did not show significant differences in the LA and AA levels.
ANOVA among the fatty acid levels of the high, intermediate, and low n-6/n-3 EN groups showed a significant dependency of the LA, EPA, DHA, and ALA concentrations on the n-6/n-3 ratio of the EN formula; the AA concentration was an exception to this relationship.
DISCUSSION
In patients receiving EN containing essential fatty acids but not EPA or DHA, meeting the EPA and DHA requirements relied entirely on in vivo biosynthesis from ALA. This nutritional situation resembles that of vegetarians, whose metabolism of essential fatty acids has been the focus of a number of investigations. The source of essential fatty acids for vegetarians is plant oils, most of which provide more LA than ALA with negligible amounts of longchain n-6 and n-3 PUFAs such as AA, EPA, and DHA (Davis and Kris-Etherton 2003) . Owing to the low ALA intake and limited conversion of ALA to n-3 PUFAs in humans, the DHA and EPA levels are lower in vegetarians than in omnivores. To increase the DHA and EPA levels, therefore, it is recommended that vegetarians consume ALA-rich oils to decrease the n-6/n-3 ratio to about 2 to 4 (Davis and KrisEtherton 2003) . In the present study, the serum concentrations of EPA and DHA were negatively correlated with the n-6/n-3 ratio of the EN formula when DHA and EPA were not included in the formula. This finding is consistent with a previous report in which switching from an EN formula with a high n-6/n-3 ratio (identical to that of the high n-6/n-3 EN group in the present study) to one with a low n-6/n-3 ratio (identical to that in the low n-6/n-3 EN group) increased the serum EPA and DHA levels within a few months in patients receiving EN (Tanaka et al. 2004) . Therefore, the biosynthesis of EPA and DHA seemed to be facilitated by EN formulas with low n-6/n-3 ratios.
The EN formulas used intermediate and high n-6/n-3 EN groups differed in that the ALA concentration was increased in the former, although the LA concentrations were high in both groups. The increase in ALA concentration in intermediate n-6/n-3 EN groups did not effectively ameliorate the serum DHA and EPA levels. Conversely, the EPA and DHA levels were significantly increased in the low n-6/n-3 EN group, which received EN formulas containing ALA concentrations that were almost the same as those in the intermediate n-6/n-3 EN group but had markedly reduced LA concentrations. Therefore, it seemed that not only increasing the ALA concentration but also simultaneously reducing the LA concentration in the EN formula effectively facilitated EPA and DHA synthesis. The conversion of ALA to EPA and DHA is suppressed by a large intake of LA (Brenna 2002) ; EPA synthesis was facilitated by lower levels of LA in the diet, whereas DHA synthesis was increased by higher levels of dietary ALA, resulting in an apparent dependency on the n-6/n-3 ratio (Goyens et al. 2006) . However, in the present study as well as in a previous report (Tanaka et al. 2004) , the effects of the reduced n-6/n-3 ratio were limited, and the serum EPA and DHA levels were still lower than those in the controls, particularly in regard to DHA.
In patients with ALA deficiency due to an EN formla containing low concentrations of ALA, supplementation with both ALA and long-chain n-3 PUFAs normalized the blood EPA and DHA status and ameliorated deficiency symptoms (Bjerve et al. 1987) . Similarly, supplementation with EPA and DHA through the consumption of fish oil effectively improved the systemic EPA and DHA status in patients with phenylketonuria (Beblo et al. 2007 ). Among vegetarians, direct supplementation with DHA effectively increased the concentration of DHA as well as that of EPA by retroconversion of DHA in blood lipids (Geppert et al. 2005; Wu et al. 2006) . Since the in vivo biosynthesis of EPA and DHA is slow and unreliable, it has been recommended that they be given as preformed nutrients in enteral nutrition (Gerster 1995) . Consistent with these previous reports, we found that the serum levels of EPA and DHA reached the control ranges in the EPA + DHA-containing EN group; this observation indicates the advantage of the direct intake of preformed EPA and DHA. Therefore, although low n-6/n-3 EN formula improved the EPA and DHA levels, EN formulas containing EPA and DHA seemed to be more effective in patients requiring long-term EN.
The data pertaining to the n-6 series showed that the AA levels in the intermediate and high n-6/n-3 EN groups did not differ from the control values, suggesting the effective in vivo formation of AA from LA. Conversely, the serum LA and AA levels in the groups receiving EN formulas containing low LA (EPA + DHA-containing and low n-6/n-3 EN groups) were significantly lower than those in the control group. Given that aberrant activation of the AA cascade can cause abnormal allergic responses and thrombotic reactions, these reduced AA levels may have desirable implications. Indeed, the use of a low-LA formula, identical to that in the low n-6/n-3 EN group in the present study, reduced coagulation and inflammatory activity after surgery (Aiko et al. 2005) . However, with the long-term use of EN, as deficiencies in LA can precipitate clinical problems (Richardson and Sgoutas 1975) , further investigation may be required to determine whether the LA intake is suitable in each patient chronically receiving a low-LA formula. In particular, in patients with limited motor activities and chronic hypothermia, the daily amount of EN can be grossly reduced to meet the low caloric requirements, which would largely restrict LA intake when a low-LA formula is used (Dickerson et al. 2003) .
In conclusion, ALA-enriched formula with low LA concentrations may facilitate EPA and DHA production in vivo, although the EN formula containing preformed EPA and DHA was more effective. The fatty acid compositions of EN formulas strongly affected the fatty acid status of the patients on long-term EN, which indicates the need for further investigation to optimize the EN formula given to these patients.
